Assessment of fibre structure & function of the heart

  • Research type

    Research Study

  • Full title

    Characterisation of Hypertrophic Cardiomyopathy with Multiparametric Magnetic Resonance Imaging and Spectroscopy

  • IRAS ID

    112814

  • Contact name

    Stefan Neubauer

  • Contact email

    stefan.neubauer@cardiov.ox.ac.uk

  • Sponsor organisation

    University of Oxford

  • Duration of Study in the UK

    8 years, 0 months, 0 days

  • Research summary

    Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterised by hypertrophy (thickening) of the heart muscle. It affects 1 in 500 individuals and is the commonest cause of sudden cardiac death in children and young adults. While the majority of patients remain asymptomatic, many develop complications, such as sudden death and heart failure. Reliable methods to distinguish who will remain well and who will be devastated by disease complications are lacking. Fibre disarray, a hallmark of HCM, has long been assumed to disrupt contraction, generate life-threatening heart rhythms and cause sudden death. However, demonstrating these direct links is limited to post mortem pathological analysis. The precise cause, prevalence, distribution and progression of fibre disarray in living HCM patients are completely unknown. Most recently, technological advances in cardiac magnetic resonance (CMR) using diffusion tensor imaging have made it possible to assess myofibre disarray in vivo in man.

    Myofibre disarray is the most pertinent feature of HCM, and has the potential to become a powerful new non-invasive risk marker. I propose to study normal volunteers, patients with HCM, three hypertrophy control groups (hypertension, aortic stenosis - narrowed heart valve, athletes) – who we suspect will have thickened hearts without fibre disarray, and patients with dilated hearts. Participants will be recruited from Oxford University Hospitals and University of Oxford, and will undergo blood tests, ECG, transthoracic echocardiography and CMR imaging. HCM patients will be asked to return for a repeat visit every 2- 5 years (maximum of 3 visits). The long-term goal is to establish disarray assessment by CMR as an important clinical tool in HCM for risk stratification and for the assessment of novel therapeutic strategies aimed at preventing development of fibre disarray. This study is funded by the British Heart Foundation and National Institute for Healthy and Research, Oxford Biomedical Research Centre.

  • REC name

    London - Central Research Ethics Committee

  • REC reference

    12/LO/1979

  • Date of REC Opinion

    24 Dec 2012

  • REC opinion

    Favourable Opinion